2022
Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer.
Chawla N, Tripathi N, Sayegh N, Govindarajan A, Dizman N, Zengin Z, Meza L, Muddasani R, Chehrazi-Raffle A, Salgia S, Malhotra J, Hsu J, Philip E, Bergerot C, Lyou Y, Swami U, Gupta S, Maughan B, Agarwal N, Pal S. Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer. Journal Of Clinical Oncology 2022, 40: 561-561. DOI: 10.1200/jco.2022.40.6_suppl.561.Peer-Reviewed Original ResearchProgression-free survivalObjective response rateImmune checkpoint inhibitorsICI therapyOverall survivalTERT promoter mutationsBladder cancerFirst-line ICI therapyImmune checkpoint inhibitor therapyAdvanced urothelial cancerSubsequent-line therapyUpper tract diseaseCheckpoint inhibitor therapySuperior overall survivalMetastatic bladder cancerMuscle-invasive diseaseTertiary cancer centerRoutine clinical careCancer Genome Atlas (TCGA) databaseLarge independent cohortsPromoter mutationsTERT mutation statusCheckpoint inhibitorsMetastatic settingVariant histologyAssociation of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC).
Meza L, Choi Y, Govindarajan A, Dizman N, Zengin Z, Hsu J, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Castro D, Chan A, Zhang G, Byron S, Highlander S, Schork N, Pal S. Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 372-372. DOI: 10.1200/jco.2022.40.6_suppl.372.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsClear cell histologyFirst-line treatmentRoutine clinical careRenal cell carcinomaT-testPaucity of dataStudent's t-testParaffin-embedded samplesICI respondersICI therapyCheckpoint inhibitorsCell histologyClinical responseOverall cohortLine treatmentImmunotherapeutic agentsCell carcinomaPoor riskSpecific bacteriaLarge cohortClinical careICI activityPrimary site
2021
Radiomic features of renal cell carcinoma primary and metastatic sites as predictors of TERT and BAP1 mutations.
Meza L, Filippov A, Naim S, Dizman N, Chehrazi-Raffle A, Philip E, Maholtra J, Muddasani R, Chawla N, Wong C, Salgia S, Karimi M, Trent J, Byron S, Chaudhry A, Pal S. Radiomic features of renal cell carcinoma primary and metastatic sites as predictors of TERT and BAP1 mutations. Journal Of Clinical Oncology 2021, 39: 282-282. DOI: 10.1200/jco.2021.39.6_suppl.282.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMetastatic sitesRenal cell carcinomaBAP1 mutationsWhole-exome sequencingRadiomic featuresCell carcinomaNon-invasive methodPrimary tumorTERT mutationsClear cell histologyPoor clinical outcomeRoutine clinical careMajority of ptsCell histologyClinical outcomesPrimary lesionClinical careMutation statusMutational statusSignificant associationCT imagingExome sequencingRadiomics analysisCancer Imaging Archive